Effect of sulindac on the permeability of the blood-retinal barrier in early diabetic retinopathy.
To study the effect of sulindac on the alteration of the blood-retinal barrier, 24 insulin-dependent diabetic patients with minimal or no retinopathy were randomly assigned to receive either oral sulindac (200 mg twice daily) or a placebo for a period of six months. All patients underwent fundus photography, fluorescein angiography, and vitreous fluorophotometry before treatment and after 1, 3, and 6 months of treatment. Vitreous fluorophotometry data showed that there were fewer alterations of the blood-retinal barrier in the sulindac group compared with the placebo group during the six-month study period.
Cunha-Vaz
J G
JG
Mota
C C
CC
Leite
E C
EC
Abreu
J R
JR
Ruas
M A
MA
D000284:Administration, Oral; D002463:Cell Membrane Permeability / Q000187:drug effects*; D002986:Clinical Trials as Topic; D003922:Diabetes Mellitus, Type 1 / Q000097:blood / Q000503:physiopathology*; D003930:Diabetic Retinopathy / Q000097:blood / Q000503:physiopathology*; D004311:Double-Blind Method; D019793:Fluorescein; D005452:Fluoresceins; D006801:Humans; D007192:Indenes / Q000494:pharmacology*; D012160:Retina / Q000187:drug effects* / Q000503:physiopathology; D012212:Rheology; D013467:Sulindac / Q000008:administration & dosage / Q000494:pharmacology*
D005452:Fluoresceins; D007192:Indenes; D013467:Sulindac; D019793:Fluorescein